Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Photoacoustic CT Scanner

By Drug Discovery Trends Editor | April 16, 2010

Endra Life Sciences has launched the Nexus 128, a preclinical photoacoustic computed tomography (CT) scanner for small animal imaging.  The system is used for simple, fast, non-invasive quantification of tumor vasculature and other physiological parameters for preclinical research.   Because the Nexus 128 makes in vivo quantification of tumor vasculature possible without the need for contrast agents, it promises to help preclinical researchers gain deeper insight into areas such as how drugs treat disease and cancer progression, without ionizing radiation or complicated equipment.

Endra Life Sciences was founded by Enlight Biosciences, a funding syndicate of six of the world’s leading pharmaceutical companies focused on commercializing transformational technologies. 

“Photoacoustic imaging combines the strengths of optical imaging, based on the same principles that give cells, organs, and tissues their unique colors, with ultrasound,”   said Michael Thornton, Endra’s President and Chief Operating Officer.   “It provides high spatial resolution at depth far exceeding that of conventional optical imaging techniques such as fluorescence and bioluminescence. We are excited to make this technology widely available to cancer biology researchers for the first time.”

“Mouse models of cancer are used extensively to study tumor development and the effects of new therapies, but until now the tools to measure this effect have had depth limitations,” said Dr. Rakesh Jain,  Director, Edwin L. Steele Laboratory for Tumor Biology at Harvard Medical School, and Enlight Biosciences Advisor.  “The ability to track abnormal vessel growth and normalization in vivo with high resolution throughout a tumor mass during therapeutic intervention is a powerful new capability that will be widely used in cancer research.” 

The name Nexus 128 represents the convergence of light and sound in a powerful new imaging approach.  It employs a detector array consisting of 128 individual acoustic receiver elements arranged in a patented geometry.  The system generates multispectral, quantitative, three dimensional images of tumor vasculature and hemoglobin concentration in under 2 minutes, and completes volumetric anatomical scans in as little as 12 seconds.  “For the past several years, our research group has developed quantitative photoacoustic spectroscopy imaging techniques and applied them to mouse models of cancer,” said Dr. Keith Stantz, faculty member of Purdue University.  “We have been using Endra’s photoacoustic tomography prototype system regularly for the past year.  The simplified animal handling and high throughput allow us to image entire study groups within a couple of hours.”

Endra Life Sciences 


Filed Under: Drug Discovery

 

Related Articles Read More >

Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE